English  |  中文
Please enter exact key words

Dedicated to the discovery and development of new therapies to enhance living standard and health

Home / Pipeline

We focus mainly on oncology. Most projects in our pipeline are at early-stage with great therapeutic and market potential.

Program Indication Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
CAR-T Therapy
GHR106-CAR-T Cancer
RP215-CAR-T Cancer
PTG-01 Acute Lymphoblastic Leukemia (ALL)
Antibody Therapy
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy (DR)
hGHR106 Cancer
RP215 Cancer
CD3XCD20 bsAb Lymphomas
Cl3hmAb Acquired Immune Deficiency Syndrome (AIDS)
Protein Therapy
P75NEURO Neurological Diseases
P11 Type 2 Diabetes
Angiocidin Acute Myeloid Leukemia
TT-173 Surgical Bleeding and Trauma
Oncolytic Virus
RV-scFv-PDL1 Cancer
OV-FV-01 Cancer

Protheragen not only incubates early drug development programs, we also manage the out-licensing process for projects developed by our partner companies. We aspire to transform the scientific innovations into medications and help patients and their family to conquer the most challenging diseases. We understand the difficulties of doing it alone.

If you are interested in any of the projects in our pipeline, please contact us for further discussion. We look forward to our collaboration.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry
Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com

Opening Hours

Monday — Sunday: 9am — 6pm